vs
Apellis Pharmaceuticals, Inc.（APLS）与Walker & Dunlop, Inc.（WD）财务数据对比。点击上方公司名可切换其他公司
Walker & Dunlop, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$340.0M vs $199.9M），Walker & Dunlop, Inc.净利率更高（-12.9% vs -29.5%，领先16.6%），Walker & Dunlop, Inc.同比增速更快（-0.4% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-680.1M），过去两年Walker & Dunlop, Inc.的营收复合增速更高（22.1% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Walker & Dunlop, Inc.是美国乃至全球规模领先的商业地产金融与咨询服务机构，为客户提供覆盖商业地产领域的多元金融解决方案及专业咨询服务，业务辐射全球多个市场，在行业内拥有深厚的资源积累与广泛的市场认可度。
APLS vs WD — 直观对比
营收规模更大
WD
是对方的1.7倍
$199.9M
营收增速更快
WD
高出5.5%
-5.9%
净利率更高
WD
高出16.6%
-29.5%
自由现金流更多
APLS
多$665.8M
$-680.1M
两年增速更快
WD
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $340.0M |
| 净利润 | $-59.0M | $-13.9M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -17.2% |
| 净利率 | -29.5% | -12.9% |
| 营收同比 | -5.9% | -0.4% |
| 净利润同比 | -62.2% | -131.0% |
| 每股收益（稀释后） | $-0.40 | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSWD
| Q4 25 | $199.9M | $340.0M | ||
| Q3 25 | $458.6M | $337.7M | ||
| Q2 25 | $178.5M | $319.2M | ||
| Q1 25 | $166.8M | $237.4M | ||
| Q4 24 | $212.5M | $341.5M | ||
| Q3 24 | $196.8M | $292.3M | ||
| Q2 24 | $199.7M | $270.7M | ||
| Q1 24 | $172.3M | $228.1M |
净利润APLSWD
| Q4 25 | $-59.0M | $-13.9M | ||
| Q3 25 | $215.7M | $33.5M | ||
| Q2 25 | $-42.2M | $34.0M | ||
| Q1 25 | $-92.2M | $2.8M | ||
| Q4 24 | $-36.4M | $44.8M | ||
| Q3 24 | $-57.4M | $28.8M | ||
| Q2 24 | $-37.7M | $22.7M | ||
| Q1 24 | $-66.4M | $11.9M |
营业利润率APLSWD
| Q4 25 | -25.6% | -17.2% | ||
| Q3 25 | 48.7% | 13.6% | ||
| Q2 25 | -18.6% | 14.5% | ||
| Q1 25 | -50.0% | 2.2% | ||
| Q4 24 | -12.3% | 15.3% | ||
| Q3 24 | -24.0% | 12.8% | ||
| Q2 24 | -14.7% | 10.4% | ||
| Q1 24 | -36.0% | 6.0% |
净利率APLSWD
| Q4 25 | -29.5% | -12.9% | ||
| Q3 25 | 47.0% | 9.9% | ||
| Q2 25 | -23.6% | 10.6% | ||
| Q1 25 | -55.3% | 1.2% | ||
| Q4 24 | -17.1% | 13.1% | ||
| Q3 24 | -29.2% | 9.9% | ||
| Q2 24 | -18.9% | 8.4% | ||
| Q1 24 | -38.5% | 5.2% |
每股收益（稀释后）APLSWD
| Q4 25 | $-0.40 | $-0.41 | ||
| Q3 25 | $1.67 | $0.98 | ||
| Q2 25 | $-0.33 | $0.99 | ||
| Q1 25 | $-0.74 | $0.08 | ||
| Q4 24 | $-0.30 | $1.32 | ||
| Q3 24 | $-0.46 | $0.85 | ||
| Q2 24 | $-0.30 | $0.67 | ||
| Q1 24 | $-0.54 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $299.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.7B |
| 总资产 | $1.1B | $5.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSWD
| Q4 25 | $466.2M | $299.3M | ||
| Q3 25 | $479.2M | $274.8M | ||
| Q2 25 | $370.0M | $233.7M | ||
| Q1 25 | $358.4M | $181.0M | ||
| Q4 24 | $411.3M | $279.3M | ||
| Q3 24 | $396.9M | $179.8M | ||
| Q2 24 | $360.1M | $208.1M | ||
| Q1 24 | $325.9M | $216.5M |
总债务APLSWD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSWD
| Q4 25 | $370.1M | $1.7B | ||
| Q3 25 | $401.2M | $1.8B | ||
| Q2 25 | $156.3M | $1.8B | ||
| Q1 25 | $164.2M | $1.7B | ||
| Q4 24 | $228.5M | $1.7B | ||
| Q3 24 | $237.1M | $1.7B | ||
| Q2 24 | $264.3M | $1.7B | ||
| Q1 24 | $266.7M | $1.7B |
总资产APLSWD
| Q4 25 | $1.1B | $5.1B | ||
| Q3 25 | $1.1B | $5.8B | ||
| Q2 25 | $821.4M | $4.7B | ||
| Q1 25 | $807.3M | $4.5B | ||
| Q4 24 | $885.1M | $4.4B | ||
| Q3 24 | $901.9M | $4.6B | ||
| Q2 24 | $904.5M | $4.2B | ||
| Q1 24 | $831.9M | $3.8B |
负债/权益比APLSWD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-664.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-680.1M |
| 自由现金流率自由现金流/营收 | -7.1% | -200.0% |
| 资本支出强度资本支出/营收 | 0.1% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-2.2B |
8季度趋势，按日历期对齐
经营现金流APLSWD
| Q4 25 | $-14.2M | $-664.3M | ||
| Q3 25 | $108.5M | $-948.1M | ||
| Q2 25 | $4.4M | $-238.5M | ||
| Q1 25 | $-53.4M | $-281.1M | ||
| Q4 24 | $19.4M | $129.4M | ||
| Q3 24 | $34.1M | $-202.0M | ||
| Q2 24 | $-8.3M | $-237.8M | ||
| Q1 24 | $-133.0M | $38.4M |
自由现金流APLSWD
| Q4 25 | $-14.3M | $-680.1M | ||
| Q3 25 | $108.3M | $-950.4M | ||
| Q2 25 | $4.4M | $-241.0M | ||
| Q1 25 | $-53.4M | $-284.7M | ||
| Q4 24 | $19.3M | $116.4M | ||
| Q3 24 | — | $-204.0M | ||
| Q2 24 | $-8.4M | $-241.7M | ||
| Q1 24 | $-133.3M | $35.2M |
自由现金流率APLSWD
| Q4 25 | -7.1% | -200.0% | ||
| Q3 25 | 23.6% | -281.5% | ||
| Q2 25 | 2.5% | -75.5% | ||
| Q1 25 | -32.0% | -120.0% | ||
| Q4 24 | 9.1% | 34.1% | ||
| Q3 24 | — | -69.8% | ||
| Q2 24 | -4.2% | -89.3% | ||
| Q1 24 | -77.3% | 15.4% |
资本支出强度APLSWD
| Q4 25 | 0.1% | 4.6% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.0% | 1.5% | ||
| Q4 24 | 0.0% | 3.8% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.0% | 1.4% | ||
| Q1 24 | 0.2% | 1.4% |
现金转化率APLSWD
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | -28.34× | ||
| Q2 25 | — | -7.02× | ||
| Q1 25 | — | -102.07× | ||
| Q4 24 | — | 2.89× | ||
| Q3 24 | — | -7.01× | ||
| Q2 24 | — | -10.49× | ||
| Q1 24 | — | 3.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
WD
暂无分部数据
